Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 2.27 EUR 3.65%
Market Cap: 197.7m EUR
Have any thoughts about
Inventiva SA?
Write Note

Inventiva SA
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inventiva SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Inventiva SA
PAR:IVA
Net Income (Common)
-€104.2m
CAGR 3-Years
-36%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Net Income (Common)
€17.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Net Income (Common)
-€34.1m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
-13%
G
Genfit SA
PAR:GNFT
Net Income (Common)
€22.3m
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Net Income (Common)
€6.6m
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Net Income (Common)
€46m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Inventiva SA
Glance View

Market Cap
197.7m EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
4.88 EUR
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Inventiva SA's Net Income (Common)?
Net Income (Common)
-104.2m EUR

Based on the financial report for Jun 30, 2024, Inventiva SA's Net Income (Common) amounts to -104.2m EUR.

What is Inventiva SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-22%

Over the last year, the Net Income (Common) growth was 5%. The average annual Net Income (Common) growth rates for Inventiva SA have been -36% over the past three years , -22% over the past five years .

Back to Top